Premium
Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes
Author(s) -
Belhadj Yassine,
Grande Pietro,
Seisen Thomas,
Gobert Aurelien,
Gomez Florie D,
Cussenot Olivier,
Roupret Morgan
Publication year - 2019
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.14647
Subject(s) - medicine , interquartile range , hazard ratio , proportional hazards model , urology , urothelial carcinoma , cuff , bladder cancer , confidence interval , cystectomy , retrospective cohort study , surgery , cancer
Objectives To assess the location of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), to determine the main predictive factors for IVR in the bladder‐cuff area (BCA), and to assess the effect of BCA recurrence (BCAR) on prognosis. Patients and methods This was a multicentre, retrospective study using the French collaborative database on UTUC, which includes data for all patients treated in 24 referral uro‐oncology centres across the country. All patients who underwent RNU with bladder‐cuff excision and who developed IVR between 1995 and 2010 were selected. Patients were divided into two groups: Group A: BCAR; and Group B: recurrence elsewhere in the bladder. The Kaplan–Meier method was used to estimate the probability of BCAR‐free survival. Groups were compared using the log‐rank test. Independent risk factors for BCAR were identified using a Cox proportional hazard regression model, with univariate and multivariate analyses. Results Overall, 163 patients were included in the final analysis: Group A, 87 patients (53.4%) and Group B, 76 (46.6%). The clinicopathological characteristics were similar in the groups. The median (interquartile range [IQR]) follow‐up was 36 (31.7–40.39) months. The median (IQR) time to IVR was 10.0 (8.6–13.39) months [Group A: 11.0 (8.8–13.2) months vs Group B: 10.0 (8.5–11.5) months; P = 0.35]. The probability of BCAR at 1, 2, and 3 years was 45.5% (95% confidence interval [CI] 40.1–50.9), 17.9% (95% CI 13.7–22.1), and 10.8% (95% CI 7.4–14.2) respectively, whereas the probability of recurrence elsewhere in the bladder was 42.1% (95% CI 36.4–47.8), 14.7% (95% CI 10.6–18.8), and 4.4% (95% CI 1.9–6.9), respectively ( P = 0.35). Pathological tumour stage (≥pT3) was significantly related to the risk of BCAR ( P = 0.03). Conclusion There were more BCARs after RNU in advanced UTUC. However, no preferred site for recurrence was detected.